biotech firms expanding glp-1 use beyond diabetes and obesity 2025 ADA '26: Lilly's dominance, Pfizer's 'foundational' drug Roche's 'me-too' option Beyond GLP-1Rs: emerging targets poised
Pay in 4 interest-free payments of $6.49 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3




























